<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00385515</url>
  </required_header>
  <id_info>
    <org_study_id>SNX-1012-CLN2-006</org_study_id>
    <nct_id>NCT00385515</nct_id>
  </id_info>
  <brief_title>Efficacy of SNX-1012 in the Treatment of Oral Mucositis</brief_title>
  <official_title>A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of SNX-1012 in Reducing the Duration and Severity of Ulcerative Oral Mucositis in Patients Receiving Cytotoxic Chemotherapy for Breast or Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mucosal Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mucosal Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral mucositis (OM) is a common and debilitating toxicity induced by many chemotherapy (CT)
      regimens and by radiation to the head and neck. The purpose of this study is to determine the
      effectiveness of SNX-1012 in decreasing the duration of Grade 2, 3, or 4 oral mucositis (OM)
      according to World Health Organization (WHO) criteria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Ulcerative Oral Mucositis</measure>
    <time_frame>At least 10 consecutive days beginning on Day 1 of a chemotherapy cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ulcerative Oral Mucositis</measure>
    <time_frame>At least 10 consecutive days beginning on Day 1 of a chemotherapy cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Stomatitis</condition>
  <condition>Oral Mucositis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SNX-1012 (meclocyline sulfosalicylate) tablets dissolved in water for oral swish and expectorate; 30 mg 4 times daily for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (matched to SNX-1012) tablets dissolved in water for oral swish and expectorate; 4 times daily for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SNX-1012 (meclocycline sulfosalicylate)</intervention_name>
    <description>tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  Naive to focal radiation therapy in the head and neck regions for cancer prior to CT
             Cycle 1. Subjects with prior or concomitant radiation therapy to areas other than the
             head and neck may be enrolled.

          -  Histologically confirmed diagnosis of breast or lung cancer (NSCLC or SCLC)

          -  Chemotherapy regimen containing AC ± T or EC ± T (for breast cancer), cisplatin or
             carboplatin (for NSCLC or SCLC), or doxorubicin (for SCLC)

          -  Subjects will receive the same regimen and dose of CT in the OM Treatment CT Cycle as
             was administered in the immediately preceding CT Cycle.

          -  Subjects will have had OM of WHO Grade of greater than or equal to 2 during CT Cycle 1
             or Cycle 2

          -  Subjects 18 years and older

          -  Karnofsky Performance Score &gt;=60

          -  Baseline laboratory assessments:

        Hemoglobin (Hgb) level &gt;= 9 g/dL Absolute neutrophil count (ANC) &gt;= 1.5 x 10 to the 9/L
        Platelet count &gt;= 100 x 10 to the 9/L Serum bilirubin level &lt;= 1.5 times institutional
        upper limit of normal (ULN) Serum aspartate aminotransferase (AST) and/or alanine
        aminotransferase (ALT) level &lt;= 2 times above ULN

          -  Females of childbearing potential must have a negative serum or urine pregnancy test
             result at the screening visit prior to the start of Cycle 1 and at the visit scheduled
             for &lt;= 48 hours prior to the start of the OM Treatment CT Cycle

          -  Subjects with reproductive capability must agree to practice adequate contraception
             methods (males must use condoms or be surgically sterilized; females must be
             surgically sterilized, post-menopausal for at least 1 year, or use an appropriate
             double barrier method, prescribed birth control oral contraceptive, patch, implant, or
             injection during the course of the study and for up to 30 days after completion of
             study assessments)

          -  Absence of other serious concurrent medical illness

          -  Psychologically able to participate and comply with study requirements

        Exclusion Criteria:

          -  Prior history of oral mucositis with previous chemotherapy treatment

          -  Previous treatment with an anthracycline agent (other than low-dose neoadjuvant
             therapy)

          -  Active liver disease or serum AST and/or ALT level &gt; 2 times above ULN

          -  Currently receiving an investigational agent, planning to receive an investigational
             agent during the study period, or received an investigational agent within 30 days of
             the first dose of SNX-1012

          -  Use of an immunosuppressive regimen of systemic corticosteroids

          -  Unwilling/unable to receive periodic oral assessments by a study evaluator or unable
             to complete the daily self-reported outcome questionnaire

          -  Pregnant or breast-feeding women

          -  Bronchoalveolar carcinoma

          -  Metastases to the central nervous system

          -  Prior or planned focal radiation therapy in the head or neck regions for the treatment
             of cancer (prior radiation to areas other than the head and neck is permitted)

          -  Presence of active or history of chronic oral mucosal disease

          -  Presence or history of any other primary malignancy (curatively treated nonmelanoma
             skin cancer is allowed)

          -  History of chronic liver disease

          -  Active hepatitis A or B

          -  Unable to receive CT during the OM Treatment CT Cycle at the same regimen and/or dose
             as in the immediately preceding CT cycle.

          -  Known sensitivity to tetracyclines

          -  Known to be seropositive for HIV or HCV

          -  Use of an immunosuppressive regimen of systemic corticosteroids.

          -  Current alcohol dependence or drug abuse

          -  Psychological, social or familial or geographical reasons that would hinder or prevent
             study visits

          -  Compromised ability to give written informed consent and/or to comply with study
             procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Desert Hematology Oncology Medical Group</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridgeport Hospital</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Hematology &amp; Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Research Cancer Institute</name>
      <address>
        <city>Davie</city>
        <state>Florida</state>
        <zip>33328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Clinic</name>
      <address>
        <city>St Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capitol Comprehensive Cancer Care Clinic</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of South Texas</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Outreach Associates</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morgantown Internal Medicine Group</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vedanta Institute of Medical Sciences</name>
      <address>
        <city>Navrangpura</city>
        <state>Ahmedabad, Gujarat</state>
        <zip>380009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jawaharlal Nehru Cancer Hospital and Research Centre</name>
      <address>
        <city>Post Box No. 32, Idgah Hills</city>
        <state>Bhopal, Madhya Pradesh</state>
        <zip>462001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Speciality Hospital</name>
      <address>
        <city>320, Mount Road, Teynampet</city>
        <state>Chennai, Tamil Nadu</state>
        <zip>600035</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dharamshila Cancer Hospital and Research Centre,</name>
      <address>
        <city>Dharamshila Marg, Vasundhara Enclave</city>
        <state>Dehli</state>
        <zip>110096</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals</name>
      <address>
        <city>Jubilee Hills</city>
        <state>Hyderabad, Andhra Pradesh</state>
        <zip>500033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizams Institute of Medical Sciences</name>
      <address>
        <city>Punjagutta</city>
        <state>Hyderabad, Andhra Pradesh</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhagwan Mahavir Cancer Hospital and Research Centre,</name>
      <address>
        <city>Jawaharlal Nehru Marg</city>
        <state>Jaipur, Rajasthan</state>
        <zip>302017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.K Sony Hospital, Vidyadhar Nagar,</name>
      <address>
        <city>Sector-5 Sikar Road</city>
        <state>Jaipur, Rajasthan</state>
        <zip>302013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netaji Subhash Chandra Bose Cancer Hospital &amp; Research Institute</name>
      <address>
        <city>16A Park Lane</city>
        <state>Kolkatta, West Bengal</state>
        <zip>700016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chittaranjan National Cancer Institute</name>
      <address>
        <city>37, S.P. Mukherjee Rd.</city>
        <state>Kolkatta, West Bengal</state>
        <zip>700026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayanand Medical College &amp; Hospital</name>
      <address>
        <city>Tagore Nagar, Civil Lines</city>
        <state>Ludhiana, Punjab</state>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jaslok Hospital &amp; Research Centre</name>
      <address>
        <city>15-Dr. G. Deshmukh Marg</city>
        <state>Mumbai, Maharashtra</state>
        <zip>400026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jehangir Hospital,</name>
      <address>
        <city>32 Sassoon Road</city>
        <state>Pune, Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruby Hall Clinic,</name>
      <address>
        <city>40, Sassoon Road</city>
        <state>Pune, Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seth Ramdas Shah Memorial Hospital &amp; Research Centre</name>
      <address>
        <city>FP-402, Gokhle Nagar Road, Shivaji Nagar</city>
        <state>Pune, Maharashtra</state>
        <zip>411016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bengal Oncology Centre,</name>
      <address>
        <city>Pradhan Nagar</city>
        <state>Siliguri, Dist- Darjeeling, West Bengal</state>
        <zip>734003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Centre</name>
      <address>
        <city>Medical College Campus, Post Bag No. 2417</city>
        <state>Trivandrum, Kerala</state>
        <zip>695011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College &amp; Hospital</name>
      <address>
        <city>IDA Scuddar Road</city>
        <state>Vellore, Tamil Nadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2006</study_first_submitted>
  <study_first_submitted_qc>October 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2006</study_first_posted>
  <results_first_submitted>January 19, 2009</results_first_submitted>
  <results_first_submitted_qc>February 17, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 18, 2009</results_first_posted>
  <last_update_submitted>April 8, 2009</last_update_submitted>
  <last_update_submitted_qc>April 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Marna Doucette</name_title>
    <organization>Coserics</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meclocycline</mesh_term>
    <mesh_term>Oxytetracycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>533 subjects were screened during a chemotherapy cycle and those that developed ulcerative oral mucositis and fully recovered were randomized to treatment with study drug during the next chemotherapy cycle</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SNX-1012</title>
          <description>SNX-1012 (meclocycline sulfosalicylate) tablets dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo tablets (matched to SNX-1012) dissolved in water for oral swish and expectorate; 4 times daily for 10 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SNX-1012</title>
          <description>SNX-1012 (meclocycline sulfosalicylate) tablets dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo tablets (matched to SNX-1012) dissolved in water for oral swish and expectorate; 4 times daily for 10 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.3" spread="12.9"/>
                    <measurement group_id="B2" value="54.5" spread="12.0"/>
                    <measurement group_id="B3" value="52.3" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Ulcerative Oral Mucositis</title>
        <description>All randomized subjects were directly observed by trained evaluators for at least 10 consecutive days during the chemotherapy cycle to document the duration for those that developed recurrent ulcerative oral mucositis</description>
        <time_frame>At least 10 consecutive days beginning on Day 1 of a chemotherapy cycle</time_frame>
        <population>Analysis only includes subjects randomized to the 30mg dose of SNX-1012</population>
        <group_list>
          <group group_id="O1">
            <title>SNX-1012</title>
            <description>SNX-1012 (meclocycline sulfosalicylate) tablets dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets (matched to SNX-1012) dissolved in water for oral swish and expectorate; 4 times daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Ulcerative Oral Mucositis</title>
          <description>All randomized subjects were directly observed by trained evaluators for at least 10 consecutive days during the chemotherapy cycle to document the duration for those that developed recurrent ulcerative oral mucositis</description>
          <population>Analysis only includes subjects randomized to the 30mg dose of SNX-1012</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="3.04"/>
                    <measurement group_id="O2" value="3.2" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ulcerative Oral Mucositis</title>
        <description>All randomized subjects were directly observed by trained evaluators for at least 10 consecutive days during the chemotherapy cycle to identify recurrence of ulcerative oral mucositis.</description>
        <time_frame>At least 10 consecutive days beginning on Day 1 of a chemotherapy cycle</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SNX-1012</title>
            <description>SNX-1012 (meclocycline sulfosalicylate) tablets dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets (matched to SNX-1012) dissolved in water for oral swish and expectorate; 4 times daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ulcerative Oral Mucositis</title>
          <description>All randomized subjects were directly observed by trained evaluators for at least 10 consecutive days during the chemotherapy cycle to identify recurrence of ulcerative oral mucositis.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Individual investigators are restricted from disclosure of results until 24 months after the completion of the Study at all participating research centers. Sponsor can review results communication prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eward G. Fey, PhD</name_or_title>
      <organization>Mucosal Therapeutics, LLC</organization>
      <phone>857-228-1100</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

